Aberdeen Group
COGT icon

Aberdeen Group’s Cogent Biosciences COGT Stock Holding History

Aberdeen Group’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$18.8M Buy
588,628
+195,394
+50% +$7.22M 0.03% 491
2026
Q2 		$15.2M Buy
393,234
+120,527
+44% +$4.22M 0.02% 516
2026
Q1 		$10.5M Buy
+272,707
New +$10.1M 0.02% 583

Other funds holding COGT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Aberdeen Group's COGT Position: Q3 2026 in Review

Aberdeen Group increased its Cogent Biosciences (COGT) stake by 50% in Q3 2026, buying an estimated $7.22M and bringing the position to 588,628 shares worth $18.8M. The position accounts for 0.03% of the portfolio, ranked #491.

Aberdeen Group first reported a position in COGT in Q1 2026 and has held it in 3 quarters since. 87 funds tracked by Wall St. Rank hold COGT as of Q3 2026.

  • Aberdeen Group held 588,628 shares of Cogent Biosciences worth $18.8M as of Q3 2026.
  • Aberdeen Group bought 195,394 Cogent Biosciences shares in Q3 2026, an estimated $7.22M.
  • Cogent Biosciences made up 0.03% of Aberdeen Group's portfolio in Q3 2026, its #491 holding.
  • Aberdeen Group first reported a position in Cogent Biosciences in Q1 2026 and has held it in 3 quarters since.
  • 87 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2026.

Based on Aberdeen Group's 13F filing for Q3 2026, filed 6 Nov 2026.